Quantifying the natural history of breast cancer

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2035-2043

  Tan, K H X ^a   Simonella, L ^a   Wee, H L ^b   Roellin, A ^b   Lim, Y W ^a   Lim, W Y ^a,c   Chia, K S ^a   Hartman, M ^a,d   Cook, A R ^a,b,e,f  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MINISTRY OF HEALTH   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f YALE NUS COLLEGE   (Singapore)

Author keywords

breast cancer; indolent ductal carcinoma in situ; Markov model; modelling; tumour size

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MONTE CARLO METHOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STATISTICAL PARAMETERS; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SWEDEN;

EID: 84885898517     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.471     Document Type: Article

References (35)

1. Albert J (2007) Bayesian Computation with R. Springer: New York, USA.
2. Blumenthal S (1967) Proportional sampling in life length studies. Technometrics 9: 205-218.
3. Brennan A, Akehurst R (2000) Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 17(5): 445-459.
4. Buist DS, Porter PL, Lehman C, Taplin SH, White E (2004) Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst 96(19): 1432-1440.
5. Chen HH, Thurfjell E, Duffy SW, Tabar L (1998) Evaluation by Markov chain models of a non-randomised breast cancer screening programme in women aged under 50 years in Sweden. J Epidemiol Community Health 52: 329-335.
6. Duffy SW, Chen H, Tabar L, Day NE (1995) Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 14: 1531-1543.
7. Duffy SW, Day NE, Tabar L, Chen H, Smith TC (1997) Markov Models of breast tumor progression: Some age-specific results. J Natl Cancer Inst Monogr 1997(22): 93-97.
8. Fagerberg G, Baldetorp L, Grontoft O, Lundstrom B, Manson JC, Nordenskjold B (1985) Effects of repeated mammographic screening on breast cancer stage distribution: Results from a randomized study of 92 934 women in a Swedish county. Acta Radiol Oncol 24(6): 465-473.
9. Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian Data Analysis, 2 edn: Chapman & Hall/CRC.
10. Gelman A, Rubin DB (1992) Inference from iterative simulation using multiple sequences. Stat Sci 7: 457-511.
11. Goulet V, Dutang C, Maechler M, Firth D, Shapira M, Stadelmann Mexpmdeveloperslists.R-forge.R-project.org (2012) expm: Matrix exponential.
12. Hastings W (1970) Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57: 97-109.
13. Haukka J, Byrnes G, Boniol M, Autier P (2011) Trends in breast cancer mortality in Sweden before and after implementation of mammography screening. PLoS One 6(9): e22422.
14. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O?Shaughnessy JA, Shen ZZ, Albain KS (2005) The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6: 391-401.
15. Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: An independent review. Lancet 380: 1778-1786.
16. Kerlikowske K (2010) Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 41: 139-141.
17. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V (1996) Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276(1): 33-38.
18. Kobrunner SH, Hacker A, Sedlacek S (2011) Advantages and disadvantages of mammography screening. Breast Care 6: 199-207.
19. Kopans DB, Smith RA, Duffy SW (2011) Mammographic screening and ?overdiagnosis?. Radiology 260: 616-620.
20. KurianAW, MunozDF, Rust P, Schackmann EA, Smith M, Clarke L,MillsMA, Plevritis SK (2012) Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 30(5): 497-506.
21. Lagerlund M, Hedin A, Sparen P, Thurfjell E, LambeM(2000) Attitudes, beliefs, and knowledge as predictors of nonattendance in a Swedish populationbased mammography screening program. Prev Med 31: 417-428.
22. Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96(12): 906-920.
23. Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD (2010) Is breast cancer the same disease in Asian and Western countries. World J Surg 34(10): 2308-2324.
24. Metropolis N, Rosenbluth A, Rosenbluth M, Teller A, Teller E (1953) Equation of state calculations by fast computing machines. J Chem Phys 21: 1087-1092.
25. Narod SA (2012) Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol 19(5): 249-253.
26. Plevritis SK, Salzman P, Sigal BM, Glynn PW (2007) A natural history model of stage progression applied to breast cancer. Stat Med 26: 581-595.
27. Plummer M, Best N, Cowles K, Vines K (2006) CODA: convergence diagnosis and output analysis for MCMC. R News 6(1): 7-11.
28. Poole D, Raftery AE (2000) Inference for deterministic simulation models: The Bayesian melding approach. J Am Stat Assoc 95(452): 1244-1255.
29. Core Team R (2012) R: A Language and Environment for Statistical Computing.
30. Straatman H, Peer PG, Verbeek AL (1997) Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 53(1): 217-229.
31. Sun X, Faunce T (2008) Decision-analytical modelling in health-care economic evaluations. Eur J Health Econ 9(4): 313-323.
32. Tabar L, Fagerberg G, Chen H, Duffy SW, Smart CR, Gad A, Smith RA (1995) Efficacy of breast cancer screening by age. new results from the Swedish two-county trial. Cancer 75(10): 2507-2517.
33. Venables WN, Ripley BD (2002) Modern Applied Statistics with S. 4th edn. Springer: New York, USA.
34. Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen H (2010) Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: Subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Res Treat 122: 553-566.
35. Zwillinger D (2011) CRC Standard Mathematical Tables and Formulae. 32 edn: (CRC Press).